Peptide safety
"Is this safe?" is the right first question. These articles look at peptide safety — what data actually exists for peptides and GLP-1 medications: what trials measured, what has only been studied in animals, how sourcing and compounding affect quality, and which red flags matter when you read claims online.
The prescription requirement exists precisely for this: a licensed provider weighs your health history before anything ships — and can say no. The same standard applies across the site: what a study measured, in whom, and for how long.
26 articles on this topic
-
How Long Does Semaglutide Stay in Your System?
Injectable semaglutide has an elimination half-life of about one week and can remain in circulation for roughly five to seven weeks after the last dose. Its effects fade on a curve, not at a single cutoff.
-
How to Inject Semaglutide Safely
Semaglutide goes into the fatty layer beneath the skin of the abdomen, front of the thigh, or back of the upper arm. The device and pharmacy label—not a generic online diagram—determine the exact technique and measured amount.
-
Thymosin Alpha-1 Dosage: What Trials Used
Published thymalfasin protocols range from 1.6 mg twice weekly for months in hepatitis studies to every-12-hour hospital regimens in sepsis. Those trial schedules explain the numbers online; they are not a personal dosing plan.
-
DSIP Dosage: What the Human Studies Used
There is no standard clinical dose for delta sleep-inducing peptide. The small human studies used intravenous infusions under observation, not a validated at-home schedule.
-
Tirzepatide Units to Mg: The Safe Conversion
Tirzepatide units to mg is not a fixed conversion. On a U-100 syringe, 20 units is 0.2 mL; the milligram amount depends on the vial concentration.
-
Tesamorelin Dosage: How Prescribers Set It
Tesamorelin is dosed daily in the trials and current brand label, but the milligram amount depends on the formulation. IGF-1, glucose, indication and tolerability matter more than a copied schedule.
-
PT-141 Dosage: What Trials and the Label Used
PT-141 is studied and labeled as an as-needed medication, not a daily routine. The practical variables are the prescribed amount, timing before anticipated activity, tolerability, and safe spacing between doses.
-
Where to Inject Tirzepatide: Abdomen, Thigh, Arm
Current Zepbound and Mounjaro labels name three subcutaneous areas: the abdomen, thigh, and back of the upper arm. This overview does not replace the product-specific instructions from the prescriber and dispensing pharmacy.
-
Compounded Semaglutide: What It Is in 2026
Compounded semaglutide is a patient-specific prescription, not a generic Ozempic or Wegovy. The ingredient form, dosing label, and post-shortage rules all matter.
-
How to Get Prescribed Peptides
The process is shorter than most people expect and has exactly one step that decides everything: a licensed provider reads your medical history and either writes the prescription or tells you no.
-
BPC-157 Side Effects and the Evidence Gap
Fewer than 30 people have taken BPC-157 in a published human study. That number, more than any list of symptoms, is the honest answer to what its side effects are.
-
Sermorelin Side Effects, by the Numbers
About one patient in six gets a reaction where the needle went in. Almost everything else on the list occurs in under 1% — but the trial data behind those numbers comes from a population that may not look like you.
-
Tirzepatide Side Effects, From Common to Rare
Gastrointestinal effects are the ones almost everyone asks about — and across the tirzepatide dose range they affect 39% to 49% of people, concentrated in the weeks when the dose is going up.
-
How to Reconstitute Peptides, Step by Step
What reconstitution involves, how the standard mixing technique works, and why your pharmacy's product-specific instructions govern every step.
-
Retatrutide and the Rise of the Triple Agonist
In its 48-week phase-2 obesity trial, retatrutide's highest dose produced an average 24.2% body-weight reduction — at publication, the largest average weight loss any obesity drug trial had reported.
-
Semaglutide Side Effects, From Common to Rare
Across pooled STEP-trial safety data, only 4.3% of adults taking semaglutide 2.4 mg stopped treatment because of gastrointestinal side effects.
-
Can You Buy Peptides Over the Counter?
No — pharmaceutical-grade peptides are prescription drugs in the U.S., and the FDA's late-2024 warning letters to sellers of research-use-only vials show how little that label protects buyers.
-
AOD-9604 Peptide: Fat-Loss Hype vs the Record
Six placebo-controlled trials in 893 obese adults — capped by a 536-subject study that missed its endpoints — ended AOD-9604's drug development in 2007.
-
Melanotan 2 Side Effects Beyond the Tan
Melanotan II's entire prospective human safety-trial record is one 1996 pilot study of three volunteers — nearly everything else comes from case reports and seized vials.
-
SS-31 Peptide: A Patient's Guide to Elamipretide
SS-31 and elamipretide are two names for the same four-amino-acid peptide, and its branded injectable form received accelerated approval from the FDA on September 19, 2025 for a single ultra-rare genetic disease.
Page 1 of 2 · 26 articles